This chapter is a preliminary part of the forthcoming book “Corona Unmasked“, and it is made available by the authors for free download for private use only. To be ordered from the publisher, a bookshop or online. All rights reserved. The authors and the publisher have prepared this work with the utmost care. Nevertheless, any liability of the publisher or the authors is excluded.


This is a pre-publication of a chapter that will be finalized in the forthcoming book, available April 2021

“Corona Unmasked” by Sucharit Bhakdi and Karina Reiss – Chapter 14 – (3715 words)

References available at:

“Gene-based vaccines received emergency approval at lightning speed to combat a virus that is no more dan-gerous than influenza (34). There is now clear evidence that people can become severely ill and die from these vaccinations. No real-world benefit of vaccination has ever been shown. Until reliable and convincing data are available, this high-risk human experiment must not be allowed to continue.”

Will good things come only to those who wait?

Until now, most of the public has accepted and sup-ported the development of vaccines without doubt and hesitation. And rightly so, since vaccinations can save lives. But no vaccination will ever be perfect and free of side effects. Useful vaccines must meet two important requirements: 1. the vaccine must offer protection against a serious or even life-threatening disease; 2. its side effects must be within tolerable and acceptable limits. On balance, the benefit must be much greater than the risk. Sounds logical, doesn’t it? And it is true. Who would get vaccinated against a common cold if this meant taking an incalculable risk of severe side effects? Furthermore, not every vaccination has to be useful for every person. Living in Germany, we do not need a vaccination against yellow fever, since it does not occur here. We already know that COVID-19 puts a clearly defined group of people at risk – namely, those over 70 with serious preexisting conditions. For these people, vaccination against SARS-CoV-2 might possibly make sense. Of course, before such vaccinations could begin, the vaccine‘s efficacy and potential dangers would need to be examined very carefully. However, the clinical studies conducted thus far have excluded precisely this group of patients, so that efficacy and risks remained unknown before the roll-out of the vaccine.

Does the “killer coronavirus” justify exceptions?